Features Partner Sites Information LinkXpress
Sign In
Demo Company

Transformative New System Brings Whole Genome Sequencing to the Desktop

By BiotechDaily International staff writers
Posted on 30 Jan 2014
Print article
Image: The NextSeq 500 System from Illumina, capable of sequencing a whole human genome in a single run, delivers the power of high-throughput sequencing with the simplicity of a desktop sequencer (Photo courtesy of Illumina).
Image: The NextSeq 500 System from Illumina, capable of sequencing a whole human genome in a single run, delivers the power of high-throughput sequencing with the simplicity of a desktop sequencer (Photo courtesy of Illumina).
A new sequencer transforms high-throughput performance into an affordable desktop form factor, enabling users to perform applications more quickly and conveniently.

Illumina (San Diego, CA, USA) now adds the NextSeq 500 System to its next-generation sequencing (NGS) portfolio. The NextSeq 500 System, currently priced at USD 250,000, delivers the flexible power of high-throughput sequencing with the load-and-go simplicity of a desktop sequencer, effectively transforming a broad range of high-throughput applications into affordable, everyday research tools.

“Illumina’s sequencing portfolio is the most comprehensive in the world, and the addition of the NextSeq 500 System furthers this distinction by enabling next-generation sequencing to become an everyday tool,” said Jay Flatley, CEO, Illumina; “The NextSeq 500 was reimagined from the ground up and uses technology breakthroughs in optics, fluidics and chemistry to bring high throughput power to the desktop at a significantly reduced cost.”

Its push-button operation delivers a one-day turnaround for several sequencing applications, including one whole human genome and up to 16 exomes, up to 20 noninvasive prenatal testing samples, up to 20 transcriptomes, up to 48 gene expression samples and up to 96 targeted panels. With its streamlined informatics, sequencing data can be run through a range of open source or commercial pipelines, or instantly transferred, analyzed, and stored securely in "BaseSpace,” or in the new "BaseSpace OnSite" for researchers needing an on premises solution.

Users also have the flexibility to switch to lower throughput sequencing as needed, and while other platforms require several pieces of specialized equipment, the NextSeq 500 System integrates cluster generation and sequencing into a single instrument. Data is generated in as little as 12 hours for a 75-cycle sequencing run and less than 30 hours for paired 150-cycle reads. The new system is supported by the full suite of Illumina sample preparation and target enrichment solutions, offering library compatibility across the entire Illumina sequencing portfolio. Its configurable output supports a wide range of applications and sample sizes with the accuracy of Illumina sequencing-by-synthesis (SBS) technology.

Related Links:


Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.